# Oscar Health, Inc.: overview

OSCR · NYSE · CIK 1568651 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/oscr.md) · [Financials](/companies/oscr/financials.md) · [Filings](/companies/oscr/filings.md) · [Insiders](/companies/oscr/insiders.md)

Latest reported revenue: [$6.1m](/filings/0001568651-26-000069.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001568651-26-000069).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [4.9](/filings/0001568651-25-000037.md) | [4.8 d](/filings/0001568651-26-000011.md) | [4.3](/filings/0001568651-26-000040.md) | [6.5](/filings/0001568651-26-000069.md) | [8.8](/filings/0001568651-25-000037.md) | [9.0 d](/filings/0001568651-26-000011.md) | [5.7](/filings/0001568651-26-000040.md) | [6.1](/filings/0001568651-26-000069.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(987.4%)](/filings/0001568651-25-000037.md) | [(3070.1%) d](/filings/0001568651-26-000011.md) | [6862.0%](/filings/0001568651-26-000040.md) | [(3547.5%)](/filings/0001568651-26-000069.md) | [(1468.6%)](/filings/0001568651-25-000037.md) | [(3722.8%) d](/filings/0001568651-26-000011.md) | [12313.5%](/filings/0001568651-26-000040.md) | [6376.3%](/filings/0001568651-26-000069.md) |
| Net margin | % | [(1114.4%)](/filings/0001568651-25-000037.md) | [(3190.9%) d](/filings/0001568651-26-000011.md) | [6357.3%](/filings/0001568651-26-000040.md) | [(3514.9%)](/filings/0001568651-26-000069.md) | [(1561.8%)](/filings/0001568651-25-000037.md) | [(3933.2%) d](/filings/0001568651-26-000011.md) | [11874.7%](/filings/0001568651-26-000040.md) | [5936.1%](/filings/0001568651-26-000069.md) |
| Diluted EPS | $ per share | [(0.22)](/filings/0001568651-25-000037.md) | not reported | [0.92](/filings/0001568651-26-000040.md) | [(0.89)](/filings/0001568651-26-000069.md) | [(0.53)](/filings/0001568651-25-000037.md) | not reported | [2.07](/filings/0001568651-26-000040.md) | [1.10](/filings/0001568651-26-000069.md) |
| Free cash flow | $m | [(508) d](/filings/0001568651-25-000037.md) | [340 d](/filings/0001568651-26-000011.md) | [870](/filings/0001568651-26-000040.md) | [500 d](/filings/0001568651-26-000069.md) | [(974) d](/filings/0001568651-25-000037.md) | [663 d](/filings/0001568651-26-000011.md) | [2,610](/filings/0001568651-26-000040.md) | [2,081 d](/filings/0001568651-26-000069.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [5.4](/filings/0001568651-24-000006.md) | [64.9](/filings/0001568651-25-000008.md) | [21.4](/filings/0001568651-26-000011.md) | [20.6](/filings/0001568651-26-000011.md) | [28.6](/filings/0001568651-26-000011.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(10094.2%)](/filings/0001568651-24-000006.md) | [(908.5%)](/filings/0001568651-25-000008.md) | [(1103.4%)](/filings/0001568651-26-000011.md) | [278.3%](/filings/0001568651-26-000011.md) | [(1386.2%)](/filings/0001568651-26-000011.md) |
| Net margin | % | [(10615.6%)](/filings/0001568651-24-000006.md) | [(933.8%)](/filings/0001568651-25-000008.md) | [(1267.9%)](/filings/0001568651-26-000011.md) | [123.6%](/filings/0001568651-26-000011.md) | [(1549.9%)](/filings/0001568651-26-000011.md) |
| Diluted EPS | $ per share | [(3.20)](/filings/0001568651-24-000006.md) | [(2.85)](/filings/0001568651-25-000008.md) | [(1.22)](/filings/0001568651-26-000011.md) | [0.10](/filings/0001568651-26-000011.md) | [(1.69)](/filings/0001568651-26-000011.md) |
| Free cash flow | $m | [(208)](/filings/0001568651-24-000006.md) | [351](/filings/0001568651-25-000008.md) | [(298)](/filings/0001568651-26-000011.md) | [950](/filings/0001568651-26-000011.md) | [1,058](/filings/0001568651-26-000011.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/oscr/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2023-08-17 | [Alphabet Inc.](/insiders/1652044.md) | 10% owner | Sale (S) | 255,092 | $8.081 | $2.1m | [Form 4](/filings/0000929638-23-002316.md) |
| 2023-08-17 | [Alphabet Inc.](/insiders/1652044.md) | 10% owner | Sale (S) | 525,470 | $8.081 | $4.2m | [Form 4](/filings/0000929638-23-002316.md) |
| 2023-08-17 | [Alphabet Inc.](/insiders/1652044.md) | 10% owner | Sale (S) | 5,719,438 | $8.081 | $46.2m | [Form 4](/filings/0000929638-23-002316.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $587.2m | 20,587,428 |  | Added +3,277,889 |
| [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $360.6m | 12,643,617 |  | Added +7,158,332 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $314.6m | 11,029,424 |  | Added +483,576 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $301.7m | 10,579,437 |  | Reduced −198,190 |
| [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $258.3m | 9,055,242 |  | Added +2,025,886 |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $181.5m | 6,365,039 |  | Added +3,460,934 |
| [Thrive Capital Management, LLC](/funds/1765681.md) | 2026-06-30 | $180.9m | 6,343,617 |  | Unchanged |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $166.0m | 5,819,186 |  | Added +786,931 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $165.5m | 5,801,351 |  | Added +538,979 |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $162.9m | 5,712,400 | Call | Added +2,229,700 |

## Recent filings

[All 583 filings](/companies/oscr/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-18 | 00:18 ET | [SCHEDULE 13D/A](/filings/0001193125-26-395843.md) | Ownership report, active investor, amended | 0001193125-26-395843 |
| 2026-09-16 | 10:02 ET | [8-K](/filings/0001568651-26-000074.md) | 7.01 Regulation FD disclosure | 0001568651-26-000074 |
| 2026-08-07 | 21:39 ET | [10-Q](/filings/0001568651-26-000069.md) | Quarterly report, period 2026-06-30 | 0001568651-26-000069 |
| 2026-08-06 | 10:08 ET | [8-K](/filings/0001568651-26-000066.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001568651-26-000066 |
| 2026-06-09 | 20:11 ET | [8-K](/filings/0001568651-26-000059.md) | 5.07 Shareholder vote results | 0001568651-26-000059 |
| 2026-06-08 | 10:29 ET | [8-K](/filings/0001568651-26-000054.md) | 7.01 Regulation FD disclosure | 0001568651-26-000054 |
| 2026-06-02 | 10:31 ET | [8-K](/filings/0001568651-26-000048.md) | 5.02 Departure or appointment of officers or directors | 0001568651-26-000048 |
| 2026-05-07 | 20:24 ET | [10-Q](/filings/0001568651-26-000040.md) | Quarterly report, period 2026-03-31 | 0001568651-26-000040 |
| 2026-05-06 | 10:19 ET | [8-K](/filings/0001568651-26-000036.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001568651-26-000036 |
| 2026-04-22 | 20:16 ET | [DEF 14A](/filings/0001140361-26-016119.md) | Proxy statement, period 2026-06-04 | 0001140361-26-016119 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001568651-26-000011.md), filed Feb 13, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/9ba3f847-7de3-4320-9f57-73bc921db7b1)

## About the filer

- CIK: 1568651
- Tickers: OSCR
- Exchange: NYSE
- SIC code: 6324 Hospital & Medical Service Plans
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.